Depression TMS Cleared for Teens; Phase III Narcolepsy Win; Fake ADHD Diagnosis?
(MedPage Today) -- Neuronetics said the FDA cleared its transcranial magnetic stimulation (TMS) device, NeuroStar, as an adjunct therapy for the first-line treatment of major depressive disorder in individuals ages 15 to 21 -- the only TMS device... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - March 27, 2024 Category: Psychiatry Source Type: news

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by the Epworth Sleepiness Scale (ESS), despite being treated 74% of treated narcolepsy type 1 patients…#bccci #depression #cns #unmetneeds #narcolepsy #narcolepsynetwork #hypersomnia #crescendo #nt1 #eds (Source: Reuters: Health)
Source: Reuters: Health - March 25, 2024 Category: Consumer Health News Source Type: news

ADHD Drug Zenzedi Recalled Over Pill Mixup
TUESDAY, Jan. 30, 2024 -- The maker of a drug used to treat ADHD and narcolepsy has recalled one lot of the medication after a pill mixup was discovered. The recall notice, issued by Azurity Pharmaceuticals Inc., states that one lot of Zenzedi... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 30, 2024 Category: General Medicine Source Type: news

Student with narcolepsy to run 70km with University pals
A student with narcolepsy will need to nap several times as he and five friends take on an epic 70km (43.5mile) run. (Source: University of Bristol news)
Source: University of Bristol news - November 30, 2023 Category: Universities & Medical Training Tags: Undergraduate, Student life, Current students; Faculty of Science; Press Release Source Type: news

Narcolepsy Med Shows Early Promise for Adult ADHD Narcolepsy Med Shows Early Promise for Adult ADHD
Solriamfetol may be a safe and effective nonstimulant treatment for adults with ADHD, results of a small, double-blind, placebo-controlled pilot study suggestMedscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - October 11, 2023 Category: Psychiatry Tags: Psychiatry News Source Type: news

Adult ADHD Trial Win; Suicide Drug Ditched; Mental Health Toll in War Zones
(MedPage Today) -- The narcolepsy drug solriamfetol (Sunosi) significantly improved attention deficit-hyperactivity disorder (ADHD) symptoms in a small randomized trial. (Journal of Clinical Psychiatry) Marking World Mental Health Day this week... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - October 11, 2023 Category: Psychiatry Source Type: news

Narcolepsy Drug, Solriamfetol, Might Be New Treatment Option for ADHD
WEDNESDAY, Oct. 11, 2023 -- A medication already approved for excessive daytime sleepiness may help ease attention-deficit/hyperactivity disorder (ADHD) symptoms in adults who aren’t getting relief from available treatments, according to a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 11, 2023 Category: General Medicine Source Type: news

Adaptive Immune Response in Narcolepsy Type 1, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insights into an overview of adaptive immune response in narcolepsy. The featured speaker will discuss determining peptide binding affinity to human leukocyte antigen (HLA). The speaker will also share insights into isolating antigen-HLA-restricted CD4+ T cells... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 27, 2023 Category: Pharmaceuticals Source Type: news

Patients With Narcolepsy Face Mood and Pain Disorders
(MedPage Today) -- NASHVILLE, Tenn. -- People with narcolepsy frequently had mood and pain comorbidities that complicated diagnosis and treatment plans, observational data showed. In a propensity-matched cohort analysis of more than 4,000 individuals... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - September 12, 2023 Category: Psychiatry Source Type: news

Orexin Receptor 2 Agonist Improves Sleepiness in Narcolepsy
THURSDAY, July 27, 2023 -- For patients with narcolepsy type 1, an orexin receptor 2 agonist, TAK-994, improves measures of sleepiness and cataplexy over eight weeks compared with placebo but is associated with hepatotoxic adverse events, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 27, 2023 Category: Pharmaceuticals Source Type: news

Narcolepsy Symptoms Normalize With Novel Agent
(MedPage Today) -- A novel drug to supply the severe lack of brain orexin neuropeptides that characterizes narcolepsy type 1 showed major efficacy in a phase II study, although safety events spelled the end of the road for the trial. Sleep latency... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - July 27, 2023 Category: Neurology Source Type: news

Peninsula drug maker's FDA lawsuit aims to stop narcolepsy drug competitor
The new drug is easier for narcolepsy patients to take, but will offer little change in price for more sodium intake, Jazz's attorneys contend. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 23, 2023 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Once-Nightly Narcolepsy Drug Preferred by Patients Over Twice-Nightly Dose
(MedPage Today) -- INDIANAPOLIS -- Extended-release sodium oxybate (Lumryz) taken once before bedtime was preferred by patients with narcolepsy over twice-nightly dosing and was generally well tolerated, according to interim data from the ongoing... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - June 6, 2023 Category: Psychiatry Source Type: news

FDA Approves Lumryz for Narcolepsy
THURSDAY, May 4, 2023 -- The U.S. Food& Drug Administration has approved Lumryz for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. Lumryz is an extended-release formulation of sodium oxybate to be taken... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 4, 2023 Category: Pharmaceuticals Source Type: news

FDA OKs Once-Nightly Sodium Oxybate for Narcolepsy FDA OKs Once-Nightly Sodium Oxybate for Narcolepsy
Extended-release sodium oxybate (Lumryz) is taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 2, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news